KimWB.JeromeD.YeungJ. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.28404701
2.
GuentherL.MetelitsaA.PrajapatiVH. Fixed combination halobetasol propionate and tazarotene lotion for plaque psoriasis. Skin Therapy Lett. 2021;26(6):1-3.34871475
3.
GoldLS.LebwohlMG.SugarmanJLet al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287-293.doi:10.1016/j.jaad.2018.03.04029614243
4.
DUOBRII™ (halobetasol propionate and tazarotene lotion) [product monograph]. Revised June 8, 2020. Bausch Health Canada Inc., Laval, QC. Accessed October 3, 2021. https://pdf.hres.ca/dpd_pm/00056991.PDF
5.
VenderR.TurchinI.LansangPet al. Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review. JAAD Int. 2022;8:60-63.doi:10.1016/j.jdin.2022.05.00135721301
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
